-
1
-
-
79952284127
-
Hallmarks of cancer: The next generation
-
D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
-
(2011)
Cell
, vol.144
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
2
-
-
84905029258
-
Comprehensive molecular profiling of lung adenocarninoma
-
The Cancer Genome Atlas Research Network
-
The Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarninoma Nature 511 2014 543 550
-
(2014)
Nature
, vol.511
, pp. 543-550
-
-
-
3
-
-
84866894408
-
Comprehensive genomic characterization of squamous cell lung cancers
-
Cancer Genome Atlas Research Network
-
Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers Nature 489 2012 519 925
-
(2012)
Nature
, vol.489
, pp. 519-925
-
-
-
4
-
-
84907270779
-
Comprehensive molecular characterization of gastric adenocarcinoma
-
Cancer Genome Atlas Research Network
-
Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma Nature 513 2014 202 209
-
(2014)
Nature
, vol.513
, pp. 202-209
-
-
-
5
-
-
84863922124
-
Comprehensive molecular characterization of human colon and rectal cancer
-
Cancer Genome Atlas Network
-
Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer Nature 487 2012 330 337
-
(2012)
Nature
, vol.487
, pp. 330-337
-
-
-
6
-
-
84877028141
-
Comprehensive molecular portraits of human breast tumours
-
Cancer Genome Atlas Network
-
Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours Nature 490 2012 61 70
-
(2012)
Nature
, vol.490
, pp. 61-70
-
-
-
7
-
-
77953930730
-
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
-
M. Maemondo, and et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N. Engl. J. Med. 362 2010 2380 2388
-
(2010)
N. Engl. J. Med.
, vol.362
, pp. 2380-2388
-
-
Maemondo, M.1
-
8
-
-
84928739294
-
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
-
P.A. Jänne, and et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer N. Engl. J. Med. 372 2015 1689 1699
-
(2015)
N. Engl. J. Med.
, vol.372
, pp. 1689-1699
-
-
Jänne, P.A.1
-
9
-
-
84903547236
-
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
-
J. Ledermann, and et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Lancet 15 2014 852 861
-
(2014)
Lancet
, vol.15
, pp. 852-861
-
-
Ledermann, J.1
-
10
-
-
84879071011
-
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
-
A.T. Shaw, and et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N. Engl. J. Med. 368 2013 2385 2394
-
(2013)
N. Engl. J. Med.
, vol.368
, pp. 2385-2394
-
-
Shaw, A.T.1
-
11
-
-
84863116743
-
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
-
J.A. Sosman, and et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N. Engl. J. Med. 366 2012 707 714
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 707-714
-
-
Sosman, J.A.1
-
12
-
-
80053539103
-
Adjuvant trastuzumab in HER2-positive breast cancer
-
D. Slamon, and et al. Adjuvant trastuzumab in HER2-positive breast cancer N. Engl. J. Med. 365 2011 1273 1283
-
(2011)
N. Engl. J. Med.
, vol.365
, pp. 1273-1283
-
-
Slamon, D.1
-
13
-
-
0037103424
-
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
-
G.D. Demetri, and et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N. Engl. J. Med. 347 2002 472 480
-
(2002)
N. Engl. J. Med.
, vol.347
, pp. 472-480
-
-
Demetri, G.D.1
-
14
-
-
84900829967
-
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs
-
M.G. Kris, and et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs JAMA 311 2014 1998 2006
-
(2014)
JAMA
, vol.311
, pp. 1998-2006
-
-
Kris, M.G.1
-
15
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
T.J. Lynch, and et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139
-
(2004)
N. Engl. J. Med.
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
-
16
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
J.G. Paez, and et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
-
17
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
T.S. Mok, and et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N. Engl. J. Med. 361 2009 947 957
-
(2009)
N. Engl. J. Med.
, vol.361
, pp. 947-957
-
-
Mok, T.S.1
-
18
-
-
79960702788
-
Biomarker analyses and final overall survival results from a Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)
-
M. Fukuoka, and et al. Biomarker analyses and final overall survival results from a Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J. Clin. Oncol. 29 2011 2866 2874
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 2866-2874
-
-
Fukuoka, M.1
-
19
-
-
56249109644
-
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised Phase III trial
-
E.S. Kim, and et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trial Lancet 372 2008 1809 1818
-
(2008)
Lancet
, vol.372
, pp. 1809-1818
-
-
Kim, E.S.1
-
20
-
-
77649222572
-
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized Phase III INTEREST trial
-
J-Y. Douillard, and et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized Phase III INTEREST trial J. Clin. Oncol. 28 2010 744 752
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 744-752
-
-
Douillard, J.-Y.1
-
21
-
-
34547638047
-
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
-
M. Soda, and et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566
-
(2007)
Nature
, vol.448
, pp. 561-566
-
-
Soda, M.1
-
22
-
-
77955174967
-
Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC)
-
Y. Bang, and et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) J. Clin. Oncol. 28 Suppl. 18 2010 3
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 3
-
-
Bang, Y.1
-
23
-
-
78049425319
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
-
E.L. Kwak, and et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N. Engl. J. Med. 363 2010 1693 1703
-
(2010)
N. Engl. J. Med.
, vol.363
, pp. 1693-1703
-
-
Kwak, E.L.1
-
24
-
-
84872569905
-
Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC)
-
Abstr. LBA1 PR
-
A.T. Shaw, and et al. Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC) Eur. Soc. Med. Oncol. Meet 2012 Abstr. LBA1 PR
-
(2012)
Eur. Soc. Med. Oncol. Meet
-
-
Shaw, A.T.1
-
25
-
-
84949502323
-
-
Vysis ALK BAP FISH Probe Kit instructions. Available at
-
Vysis ALK BAP FISH Probe Kit instructions. Available at: http://www.accessdata.fda.gov/cdrh-docs/pdf11/P110012c.pdf
-
-
-
-
26
-
-
84949524462
-
-
FDA Drug Approvals And Databases. Available at
-
FDA Drug Approvals And Databases. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/
-
-
-
-
27
-
-
84949484036
-
-
FDA List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). Available at
-
FDA List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). Available at: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm
-
-
-
-
28
-
-
84949485423
-
-
FDA Nucleic Acid Based Tests. Available at
-
FDA Nucleic Acid Based Tests. Available at: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm330711.htm
-
-
-
-
29
-
-
84949522424
-
-
European Medicines Agency (EMA) approvals. Available at
-
European Medicines Agency (EMA) approvals. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/landing/human-medicines-regulatory.jsp&mid
-
-
-
-
30
-
-
84949499089
-
-
Report The Academy of Medical Sciences. Available at
-
Report The Academy of Medical Sciences. Available at: https://www.acmedsci.ac.uk/viewFile/51e915f9f09fb.pdf
-
-
-
-
31
-
-
84949505797
-
-
Report Association of the British Pharmaceutical Industry (ABPI). Available at
-
Report Association of the British Pharmaceutical Industry (ABPI). Available at: http://www.abpi.org.uk/our-work/library/medical-disease/Documents/strat-med.pdf
-
-
-
-
32
-
-
79957857433
-
The BATTLE trial: Personalizing therapy for lung cancer
-
E.S. Kim, and et al. The BATTLE trial: personalizing therapy for lung cancer Cancer Discov. 1 2011 44 53
-
(2011)
Cancer Discov.
, vol.1
, pp. 44-53
-
-
Kim, E.S.1
-
33
-
-
84865191389
-
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
-
L.J. Esserman, and et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) Breast Cancer Res. Treat. 132 2012 1049 1062
-
(2012)
Breast Cancer Res. Treat.
, vol.132
, pp. 1049-1062
-
-
Esserman, L.J.1
-
34
-
-
84856522259
-
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: Results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657
-
L.J. Esserman, and et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657 J. Clin. Oncol. 30 2012 3242 3249
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 3242-3249
-
-
Esserman, L.J.1
-
35
-
-
84862501734
-
Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy - Results from ACRIN 6657/I-SPY TRIAL
-
N.M. Hylton, and et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy - results from ACRIN 6657/I-SPY TRIAL Radiology 263 2012 663 672
-
(2012)
Radiology
, vol.263
, pp. 663-672
-
-
Hylton, N.M.1
-
36
-
-
84865188320
-
Locally advanced breast cancers are more likely to present as interval cancers: Results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial)
-
C. Lin, and et al. Locally advanced breast cancers are more likely to present as interval cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial) Breast Cancer Res. Treat. 132 2012 871 879
-
(2012)
Breast Cancer Res. Treat.
, vol.132
, pp. 871-879
-
-
Lin, C.1
-
37
-
-
84949510980
-
-
MATRIX National Lung Cancer Trial, Cancer Research, UK. Available at
-
MATRIX National Lung Cancer Trial, Cancer Research, UK. Available at: http://scienceblog.cancerresearchuk.org/2014/04/17/stratified-medicine-and-the-lung-cancer-matrix-trial-part-of-a-cancer-care-revolution/
-
-
-
-
38
-
-
84949512475
-
-
Lung-MAP, Lung Master Protocol, Friends of Cancer Research, US. Available at
-
Lung-MAP, Lung Master Protocol, Friends of Cancer Research, US. Available at: http://www.focr.org/lung-map
-
-
-
-
39
-
-
84927177712
-
The AURORA initiative for metastatic breast cancer
-
D. Zardavas, and et al. The AURORA initiative for metastatic breast cancer Br. J. Cancer 111 2014 1881 1887
-
(2014)
Br. J. Cancer
, vol.111
, pp. 1881-1887
-
-
Zardavas, D.1
-
40
-
-
84949524298
-
-
Japan National Cancer Centre. Available at
-
Japan National Cancer Centre. Available at: http://www.ncc.go.jp/en/index.html
-
-
-
-
41
-
-
84949500709
-
-
EORTC, Colorectal Cancer Screening Platform, SPECTAColor. Available at
-
EORTC, Colorectal Cancer Screening Platform, SPECTAColor. Available at: http://spectacolor.eortc.org/
-
-
-
-
42
-
-
84949500407
-
-
EORTC, SPECTALung Available at
-
EORTC, SPECTALung Available at: http://www.eortc.org/news/eortc-through-spectalung-participates-in-european-consortium-validating-blood-based-cancer-biomarkers/
-
-
-
-
43
-
-
84949525401
-
-
National Cancer Institute (NCI), US, NCI-MATCH (Molecular Analysis for Therapy Choice). Available at
-
National Cancer Institute (NCI), US, NCI-MATCH (Molecular Analysis for Therapy Choice). Available at: http://www.cancer.gov/researchandfunding/areas/clinical-trials/nctn/match
-
-
-
-
44
-
-
84885021119
-
Considerations for the successful co-development of targeted cancer therapies and companion diagnostics
-
J. Fridlyand, and et al. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics Nat. Rev. Drug. Discov. 12 2013 743 755
-
(2013)
Nat. Rev. Drug. Discov.
, vol.12
, pp. 743-755
-
-
Fridlyand, J.1
-
45
-
-
84949514097
-
-
Shaw, A.T. The Crizotinib Story: From Target to FDA Approval and Beyond. InforMEDical report. Available at
-
Shaw, A.T. The Crizotinib Story: From Target to FDA Approval and Beyond. InforMEDical report. Available at: http://www.informedicalcme.com/lucatoday/crizotinib-story-from-target-to-fda-approval/
-
-
-
-
46
-
-
84906273146
-
Crizotinib: A comprehensive review
-
A. Sahu, and et al. Crizotinib: a comprehensive review South Asian J. Cancer 2 2013 91 97
-
(2013)
South Asian J. Cancer
, vol.2
, pp. 91-97
-
-
Sahu, A.1
-
47
-
-
84949497802
-
-
United States, Food and Drug Administration Safety and Innovation Act (FDASIA) Section 902; Breakthrough Therapy Designation. Available at.
-
United States, Food and Drug Administration Safety and Innovation Act (FDASIA) Section 902; Breakthrough Therapy Designation. Available at: http://www.fda.gov/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/FDASIA/ucm329491.htm.
-
-
-
-
48
-
-
84896957081
-
Ceritinib in ALK-rearranged non-small-cell lung cancer
-
A.T. Shaw, and et al. Ceritinib in ALK-rearranged non-small-cell lung cancer N. Engl. J. Med. 370 2014 1189 1197
-
(2014)
N. Engl. J. Med.
, vol.370
, pp. 1189-1197
-
-
Shaw, A.T.1
-
49
-
-
84878347085
-
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): A single-arm, open-label, phase 1-2 study
-
T. Seta, and et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study Lancet Oncol. 14 2013 590 598
-
(2013)
Lancet Oncol.
, vol.14
, pp. 590-598
-
-
Seta, T.1
-
50
-
-
84899489162
-
Direct-to-consumer genetic testing and personal genomics services: A review of recent empirical studies
-
J.S. Roberts, and J. Ostergren Direct-to-consumer genetic testing and personal genomics services: a review of recent empirical studies Curr. Genet. Med. Rep. 1 2013 182 200
-
(2013)
Curr. Genet. Med. Rep.
, vol.1
, pp. 182-200
-
-
Roberts, J.S.1
Ostergren, J.2
-
51
-
-
84949508567
-
-
Cure Forward Available at
-
Cure Forward Available at: http://cureforward.com/
-
-
-
-
52
-
-
84949516420
-
-
Foundation Medicine, Connect - Patients and Caregivers. Available at
-
Foundation Medicine, Connect - Patients and Caregivers. Available at: http://www.mycancerisunique.com/
-
-
-
|